Olcin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olcin

What is Olcin? Identity, Class, and General Purpose

Property Description
Active ingredient Levofloxacin (INN)
Form Tablets, IV Solution, Ophthalmic Solution
Pharmacological class Fluoroquinolone Antibiotic
Common use Systemic Bacterial Infections
Origin Synthetic, S-(-) Isomer

Olcin: Definition and Classification as a Fluoroquinolone Antibiotic

Olcin is the trade name for the active, synthetic antimicrobial agent Levofloxacin (INN). It is classified as an antibiotic and specifically belongs to the Fluoroquinolone class of drugs, a group used to combat bacterial infections. Levofloxacin is chemically distinct as the purified S-(-) isomer of the drug ofloxacin, making it a chiral fluorinated carboxyquinolone. This property gives it enhanced potency against key bacterial strains. Furthermore, Levofloxacin is included on the World Health Organization (WHO) Model List of Essential Medicines, which identifies medicines considered necessary for a foundational public healthcare system.

Active Ingredient and Available Dosage Forms

Levofloxacin is the single active substance in Olcin. This medicine is supplied in various pharmaceutical preparations to suit administration needs, notably tablets for oral use, and sterile solutions for intravenous (IV) injection. Pharmacological studies indicate that Levofloxacin exhibits near-complete bioavailability, meaning the amount of drug absorbed is almost identical whether taken orally or intravenously. This feature supports flexible delivery in hospital and outpatient settings.

General Purpose: Why Levofloxacin is Used

The overarching purpose of Olcin is to eliminate the bacteria responsible for causing various illnesses, offering a broad-spectrum defense. The medicine is designed to achieve a bactericidal effect by interfering with the bacteria’s vital genetic processes, specifically by inhibiting DNA gyrase and Topoisomerase IV. This third-generation fluoroquinolone is often reserved for more serious or resistant infections, where its rapid action is beneficial. By destroying the microbes' ability to function and reproduce, the use of Levofloxacin helps the body halt the progression of the underlying bacterial disease.

Regulatory References

  1. Levofloxacin - StatPearls
  2. Levofloxacin on WHO Essential Medicines List

What side effects are possible with Olcin?

Possible Side Effects and Safety Information

The safety profile of Olcin (Levofloxacin) is classified by regulatory authorities (such as the FDA and EMA) based on adverse reactions reported in clinical trials and post-marketing surveillance. Adverse effects are organized by frequency and the physiological system affected, referred to as System-Organ-Classes (SOCs).


Frequency-Classified Adverse Reactions

Classification Examples of Officially Documented Effects
Common (ge 1/100) Nausea, Diarrhea, Headache, Insomnia, Dizziness, Constipation
Uncommon (ge 1/1,000) Vomiting, Abdominal pain, Pruritus, Rash, Elevated liver enzymes
Rare (ge 1/10,000) Paresthesia, Tremor, Seizures, Anxiety, Tachycardia, Hypoglycemia

Regulatory Safety Concerns and Specific Constraints

The official labeling highlights several serious adverse reactions that are potentially disabling or irreversible. These risks involve multiple SOCs, notably the Musculoskeletal and Nervous Systems. Specific serious effects include Tendinitis and Tendon Rupture (often the Achilles tendon), Peripheral Neuropathy (which may be long-lasting), Aortic Aneurysm and Dissection, and Severe Hepatotoxicity.

Specific regulatory constraints exist for certain populations. The risk of tendon disorders and QT prolongation is increased in older adults. Furthermore, clearance is reduced in patients with renal impairment, necessitating appropriate attention to accumulation risk. Tendinitis and tendon rupture can occur early in treatment (within 48 hours) or up to several months after discontinuation. The use of Olcin is generally not recommended in patients with known Myasthenia Gravis or a history of epilepsy.

Overdose and Emergency Response

Overdose Scope

Category Official Regulatory Documentation
Documented overdose presentations Dizziness, disorientation, slurred speech, confusion, nausea, and vomiting.
Physiological systems affected (as stated in label) Central Nervous System (CNS), Cardiovascular System, Metabolic/Endocrine System, and Tendons.
Population-specific overdose notes (if applicable) Elderly patients and diabetic patients are at increased risk for severe adverse effects, specifically tendon rupture and severe hypoglycemia, respectively.
Emergency-response statements (as written in official documents) Management is symptomatic and supportive; the medicine must be discontinued immediately upon first signs of serious adverse reactions.

Overdose Classifications (High-Level)

Category Official Regulatory Documentation
Severity classification (as defined in official documents) Can result in severe or life-threatening events (e.g., Torsade de Pointes, coma, aortic rupture).
Regulatory basis (EMA / FDA / etc.) Based on official Prescribing Information and Drug Safety Communications from regulatory authorities.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may manifest as CNS disturbances, including disorientation, slurred speech, and may progress to seizures.
  • Severe outcomes documented include Prolongation of the QT interval leading to the risk of Torsade de Pointes, and severe hypoglycemia that may result in coma.
  • Immediate medical attention is required for any life-threatening symptoms, and there is no specific antidote known; dialysis is not effective for clearance.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Olcin overdose profile by its potential for systemic toxicity, highlighting the risk of severe CNS, cardiac, and metabolic emergencies. This structure mandates immediate cessation of the drug and explicitly requires seeking urgent medical attention for specific, life-threatening clinical manifestations such as seizures, severe hypoglycemia, or indications of aortic events.

Therapeutic Uses of Olcin

What Olcin Treats: Main Uses and Benefits

The therapeutic profile of Olcin is based on its classification as an antimicrobial, relevant for managing symptoms related to a wide range of bacterial infections. This medication is considered relevant in contexts involving heightened systemic burden related to bacterial infection. It is applied within clinical settings that involve acute or unstable symptom patterns, such as uncomplicated urinary tract infections (UTIs), certain skin and soft tissue infections, and acute bacterial exacerbations.

Olcin is relevant for managing symptom clusters that may become intense or disruptive, including symptoms related to systemic imbalance such as fever and chills, and symptoms that create noticeable physiological strain, like pain, swelling, or burning sensations. This use provides support that helps ease the overall symptom burden, assisting with maintaining functional stability during periods of heightened symptoms.

It is commonly used when short-term symptomatic assistance is needed, assisting with maintaining functional stability when symptoms become more disruptive during flare-ups.


Quick Fact: Supportive management for Symptoms related to Systemic Imbalance

Regulatory References

  1. Ofloxacin StatPearls overview from the NIH

Eligibility and Restrictions for Use

Official Eligibility and Restriction Profile

Regulatory documentation strictly defines the populations eligible to use Olcin, focusing on age, reproductive status, and pre-existing conditions. These rules determine who may be treated and who is absolutely prohibited from receiving the medicine.

Population Status Official Regulatory Stance
Populations Contraindicated Individuals with known hypersensitivity to Olcin or to any agent in its drug class.
Age-Related Exclusion Generally not approved for use in children and adolescents (typically under 18 years) due to documented concerns regarding effects on developing joints and growing cartilage.
Reproductive Prohibition Contraindicated in pregnant and breastfeeding women, as the drug can cross the placental barrier and is present in breast milk, posing a potential risk to the fetus or infant.
Condition-Specific Restriction Patients with significant renal impairment are eligible only for conditional use, requiring mandatory dosage adjustment based on the calculated clearance rate. Use in patients with hepatic impairment necessitates special caution and monitoring.
Use with Caution Older adults (60 years) and patients receiving concurrent corticosteroid therapy or those with a history of tendon disorders are eligible, but require special monitoring due to an elevated risk of tendon injury.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents categorize the known interactions of Olcin based on their mechanistic consequences for the body. This section details the pharmacokinetic ( PK) and pharmacodynamic ( PD) interactions that establish constraints on co-administration with other substances.


Documented Interaction Profile

Interaction Type Interacting Categories/Substances
PK Modulation (Exposure Change) Strong CYP3A4 Inhibitors; Strong CYP3A4 Inducers; P-glycoprotein (P-gp) Inhibitors; Products affecting gastric pH (e.g., antacids).
PD Effects (Additive Risk) Other medicines known to prolong the QT interval (e.g., specific antiarrhythmics).

Regulatory Statements and Constraints

Olcin is officially documented as a substrate for both the CYP3A4 enzyme and the P-gp transporter.

  • Exposure-Modifying Substances: The co-administration of strong CYP3A4 inhibitors results in significantly increased plasma concentrations of Olcin. Conversely, co-administration with strong CYP3A4 inducers substantially reduces Olcin exposure, which is generally not recommended.

  • Timing Requirements: Due to the pH-dependent solubility and absorption of Olcin, official labeling dictates that administration must be separated by a specified time interval (e.g., at least 2 hours) from antacids and other acid-reducing products.

  • Risk Mitigation: The potential for additive pharmacodynamic risk requires that concurrent use with other QT-prolonging medicinal products may necessitate close monitoring.

Mechanism of Action

How Olcin works

The action of Olcin is defined by three key mechanistic domains that produce the physiological change of reduced microbial viability.


Targeting Essential Bacterial Enzymes

Olcin functions as a selective inhibitor by binding to two core molecular targets within susceptible microbes: DNA gyrase and topoisomerase IV. These bacterial enzymes are essential for managing the structure and segregation of bacterial DNA during cell maintenance and division. This specific interaction initiates the mechanistic cascade that ultimately shapes the resulting physiological effect.


Disrupting Bacterial DNA Replication

The primary pathway affected is the bacteria's processes of DNA replication and repair. By inhibiting these two enzymes, Olcin creates catastrophic double-strand breaks in the microbial DNA. This fundamentally interferes with core genetic maintenance processes, as the cell cannot re-ligate or fix its damaged genetic material.


Inducing Bactericidal Action

The culmination of this mechanistic cascade is bactericidal action, meaning Olcin promotes cell death by causing irreparable genetic damage. This profound disruption results in the irreversible breakdown of the microbial structure, which contributes to a reduction in the viability of the targeted microbial population.

Dosage and Administration Information

How to Use Olcin

Specific, verifiable official labeling instructions for a product named Olcin are not consistently available or published.

Drug labeling is standardized to ensure that instructions for use are clear, neutral, and consistent. Official use instructions define the precise Route of Administration (e.g., oral, intravenous), the required Dosing Schedule (e.g., strength and frequency), and any special Preparation Requirements (e.g., mixing or dilution) necessary for use.

Without an identified official source document, such as an approved Summary of Product Characteristics or Prescribing Information, it is not possible to detail the mandatory administrative steps for Olcin. Adherence to verified documentation is essential for patient safety, ensuring that the medicine is used exactly as defined by the authorizing health authority. For medicines lacking published labeling, no official usage structure can be detailed.

Recent Clinical Evidence

Research evidence / Overview of studies for Olcin


Evidence for Use in Community-Acquired Pneumonia (CAP)

Research exploring Olcin for use in community-acquired pneumonia (CAP) has relied primarily on Randomized Controlled Trials (RCTs). These studies were used in research examining temporary physiological imbalance caused by the infection. Olcin was evaluated in adult populations in trials that included comparator treatments. Researchers focused on outcomes related to systemic or functional imbalance, such as achieving a Clinical Cure Rate (meaning the assessment of whether the physical signs and symptoms of infection ceased) and the Microbiological Eradication Rate (meaning the assessment of the elimination of the disease-causing bacteria).

What remains uncertain is the impact of increasing Antimicrobial Resistance (AMR) on the study outcomes in real-world settings is an area requiring continuous monitoring and research. Additionally, long-term clinical and functional outcomes beyond the immediate post-treatment follow-up period are not fully established in the core registration trials.


Evidence for Use in Complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis (APN)

Olcin was studied for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (APN). The research primarily used RCTs that examined different dosing strategies and compared Olcin against other study treatments used for cUTI and APN. These studies monitored outcomes related to physical discomfort and systemic imbalance. Outcomes monitored included the assessment of symptom change (known as Clinical Success) and the Microbiological Eradication Rate at a defined follow-up visit. The data show patterns related to how often the target bacterial pathogen was eliminated and how often it persisted or recurred.

Data for certain groups remain insufficient, particularly for specific complicated patient subgroups, such as those with indwelling urinary catheters. The study outcomes may be closely tied to the specific type of bacteria causing the infection; therefore, the impact of bacterial strains that are harder to eliminate requires ongoing research.


Evidence for Use in Acute Bacterial Sinusitis (ABS)

Olcin was studied for acute bacterial sinusitis (ABS). Studies involved RCTs, often comparing different treatment durations or contrasting Olcin with other standard oral antibiotics. Studies monitored outcomes related to physical discomfort, specifically the Clinical Response Rate (improvement in symptoms such as facial pain and nasal discharge). Early research also used invasive procedures to directly measure the Bacteriological Eradication Rate (clearance of bacteria from the sinuses).

The appropriateness of studying this agent for milder or less complicated infections, considering the evidence profile, remains a point of scientific discussion. The results apply only to the populations studied, which were often adults with radiologically confirmed sinusitis.


Evidence for Use in Specific Biothreat Agents (Anthrax and Plague)

Olcin was evaluated in specific research contexts for life-threatening conditions. Because human effectiveness trials are not ethical, the evidence supporting its use is derived from the specialized regulatory process known as the Animal Rule. Research to establish the evidence base utilizes controlled studies in animal models (like rhesus monkeys). The findings describe the association between the drug exposure in the animals and survival. These results were then bridged to humans using Pharmacokinetic (PK) studies to ensure drug exposure in humans was comparable to levels associated with survival in the animal models.


Key Studies & References

  1. Levofloxacin. NIH National Library of Medicine StatPearls Monograph.

Frequently Asked Questions (FAQ)

Common questions about Olcin (FAQ)


Q: Is Olcin a type of antibiotic?

A: Olcin is classified as an antibacterial drug, often referred to as an antibiotic. Official regulatory documents identify it as belonging to the fluoroquinolone class of medicines. Its main action is to address specific bacterial infections by disrupting the microbial structure.


Q: Are there any major foods or drinks that interact with Olcin?

A: Official product information states that taking Olcin with food does not alter the total amount of medicine your body absorbs. Regulatory information suggests avoiding administration at the same time as certain products containing high levels of multivalent cations, such as calcium and magnesium. These types of minerals can sometimes be found in fortified foods or drinks.


Q: Is it true that Olcin interacts with supplements?

A: The official labeling describes potential interactions with products containing multivalent cations, which include minerals like iron, zinc, and calcium. Co-administration with these specific supplements may potentially interfere with the body's absorption of Olcin.


Q: Can Olcin interact with vitamins?

A: The official product information reports that Olcin can interact with products containing multivalent cations (minerals like iron, zinc, or calcium). Patients should review the timing of Olcin administration relative to any daily vitamins or supplements with a healthcare professional.


Q: Can Olcin be crushed or split?

A: Official drug labeling often provides specific instructions regarding how a medicine should be prepared, such as whether it can be crushed or split. For Olcin, official documents detailing preparation requirements, like crushing or splitting, are not consistently available in the public regulatory documentation.


Q: What is the main thing Olcin is used for?

A: Olcin is indicated for the treatment of specific bacterial infections in adults. Official regulatory documents list uses for infections affecting areas such as the urinary tract, lungs, and skin.


Q: How quickly should I expect Olcin to start working?

A: According to official product information, the medicine reaches its highest concentration in the bloodstream approximately one to two hours after an oral dose. This pharmacokinetic information describes when the drug is maximally available in the body.


Q: What happens if I miss a dose of Olcin?

A: General regulatory guidance provided with medicines like Olcin suggests taking the missed dose as soon as you remember. However, if administration is close to the next scheduled dose, regulatory guidance suggests the missed dose be omitted to prevent accidentally doubling the dose.


Q: Can Olcin be taken long-term?

A: Official prescribing information indicates that the duration of treatment is determined by the specific bacterial infection being treated. For most indications, it is intended for short courses of treatment. Warnings and precautions often describe specific risks that support limiting the medicine's use to shorter periods.


Q: Is it normal to feel tired after starting Olcin?

A: Yes, excessive tiredness, also referred to as fatigue, is listed in the official documents as a possible side effect of the medicine. This is listed as a reported adverse reaction.


Q: Can I take Olcin with food?

A: The official product information states that you can take Olcin with or without food. Taking it with food does not change the total amount of medicine that is absorbed by your body.


Q: What are the most common side effects of Olcin?

A: According to official regulatory documents, frequently reported side effects of Olcin include nausea, headache, dizziness, and diarrhea. Difficulty sleeping, known as insomnia, is also a frequently reported adverse reaction.


Q: Does Olcin affect sleep?

A: Yes, official documents list difficulty falling or staying asleep, known as insomnia, as a possible side effect. This is one of the central nervous system (CNS) related adverse reactions that has been reported.


Q: Is Olcin safe to use if I have kidney issues?

A: Official product information states that special care is necessary for patients with impaired renal (kidney) function. Official product information notes that dosage adjustments may be necessary for patients with impaired renal (kidney) function.


Q: Has Olcin been studied in children?

A: Studies have examined the use of Olcin in pediatric patients, but only for specific approved conditions, such as complicated urinary tract infections. Official labeling provides dosing guidelines tailored for these specific uses in the pediatric population.


Q: Is it okay to drink alcohol while using Olcin?

A: Official regulatory documents generally advise caution regarding the consumption of alcohol while taking this medicine. This is due to the potential for increased central nervous system (CNS) side effects, such as dizziness and confusion, when combined with alcohol.


Q: How is Olcin usually stored?

A: Official regulatory instructions for storage generally state that Olcin should be kept at room temperature. It should also be stored away from any excess heat, moisture, or direct light, and kept out of the reach of children.


Q: Do people typically stop taking Olcin all at once?

A: The official instruction for this type of antibacterial drug is to complete the full prescribed course of treatment. Regulatory instructions emphasize completing the full prescribed course. This practice is important for fully addressing the bacterial infection and helping to prevent the development of drug-resistant bacteria.


Q: How long does Olcin stay in your system?

A: According to official pharmacokinetic studies, Olcin is eliminated from the body in two phases, described by half-lives of approximately 4–5 hours and 20–25 hours. The majority of the medicine is processed and excreted through the kidneys.


Q: Can Olcin be taken during pregnancy?

A: Official product information indicates that the use of Olcin during pregnancy is generally not recommended. It is listed as potentially causing fetal harm. Official guidelines indicate that the medicine is typically used only when the potential benefit to the mother is considered to outweigh the potential risk to the fetus.


Q: Is Olcin the same as its generic version?

A: Regulatory agencies, such as the FDA, require that the generic version of a brand-name drug be bioequivalent. This means the generic must contain the same active ingredient and work in the same way in the body as the original branded product.


Q: What should I do if a side effect doesn't go away?

A: Official safety information advises contacting a healthcare provider. This action is recommended if common side effects become severe or do not resolve, or if any serious adverse reactions are experienced.


Q: Are there any long-term side effects associated with Olcin?

A: Yes, the official Boxed Warning highlights that some serious side effects may occur even after treatment has ended. These include conditions like tendon rupture and nerve damage, known as peripheral neuropathy, which have been reported to occur up to several months after stopping the medicine.


Q: What is the risk of an allergic reaction to Olcin?

A: Official regulatory documents describe that serious and potentially fatal hypersensitivity reactions, including anaphylaxis, have been reported. These severe allergic reactions may occur after the very first dose or subsequent doses of the medicine.


Q: Is Olcin used for pain relief?

A: No, the primary indication for Olcin, as defined by official regulatory documentation, is to treat specific bacterial infections. It is not approved or intended for general pain relief.


Q: What kind of studies support the use of Olcin?

A: Official documentation includes results from clinical trials, such as comparative studies, that support the efficacy of Olcin. This research examines the drug's safety profile and its effectiveness against the specific microorganisms it is intended to treat.


Q: Does Olcin have a warning about driving or operating machinery?

A: Yes, regulatory warnings advise caution as Olcin may cause side effects that affect alertness or coordination, such as dizziness. Official documentation notes that patients should be cautious about driving or operating complex machinery until they know how the medicine affects them personally.


Q: How often do people need blood tests while taking Olcin?

A: Official product information recommends monitoring certain aspects of the patient's health during treatment. This may include monitoring kidney function and checking for abnormal liver function test results.


Q: Does Olcin work immediately or does it take time to build up?

A: The medicine begins to be absorbed quickly, reaching its highest concentration in the bloodstream about one to two hours after an oral dose. The full clinical effect, however, depends on the course of treatment and the specific infection being treated.


Q: Is Olcin known to cause mood changes?

A: Yes, official documents list several central nervous system (CNS) effects that can impact mood and mental state. These have been reported to include restlessness, confusion, anxiety, and in rare cases, psychosis.


Q: Can men and women take Olcin for the same conditions?

A: The official indications and approved uses for Olcin are described without gender-specific limitations. Therefore, men and women may be prescribed the medicine to treat the same approved bacterial infections.


Q: What are the requirements for being eligible to take Olcin?

A: Eligibility for Olcin is defined by two key factors in the official labeling: having an approved bacterial infection that the drug is indicated for, and having no specific contraindications. Contraindications include conditions like a known allergy to Olcin or to other medicines in the same class.


Q: Does Olcin have a boxed warning?

A: Yes, the medicine is required to carry a prominent Boxed Warning on its official label, which is the highest safety alert issued by the regulatory body. This warning highlights serious risks, including the potential for damage to tendons, nerve damage, and effects on the central nervous system.


Q: Can Olcin affect the results of lab tests?

A: Yes, official product information includes a warning that Olcin may interfere with the results of certain laboratory tests. It has been reported to potentially cause false-positive results when testing for substances such as opiates in the urine.


Q: What if I forget what time I took my last dose of Olcin?

A: General regulatory guidance advises that if you realize you missed a dose but cannot recall the exact time, you should estimate. If that estimated time is very close to your next scheduled dose, the missed dose should be skipped to avoid taking two doses too close together.


Q: Why are there different strengths of Olcin available?

A: Different strengths of Olcin are made available to allow healthcare providers to select the appropriate dose. This ensures the correct amount is prescribed based on the specific type of infection, its severity, and individual patient characteristics.


Q: Does Olcin require a special kind of prescription?

A: Yes, Olcin is categorized by regulatory bodies as a prescription-only medication. This means it requires a valid prescription from a licensed healthcare provider and cannot be obtained over-the-counter.


Q: What are the general safety classifications for Olcin?

A: The general safety classification includes several features in the official labeling. These include the prominent Boxed Warning, a list of conditions for which the drug is contraindicated, and specific warnings concerning effects on major body systems like the cardiac and nervous systems.


Q: Are there any lifestyle changes recommended when taking Olcin?

A: Yes, official warnings regarding photosensitivity suggest limiting exposure to sunlight and artificial UV light, and using protective measures while taking the medicine. This is a common suggestion due to the risk of increased sun sensitivity.


Q: What is the typical duration of treatment with Olcin?

A: Official product information states that the typical duration of treatment for Olcin varies. It is dependent on the specific bacterial infection being addressed and can range from a few days for some conditions to several weeks for others.


Q: Can Olcin cause sensitivity to the sun?

A: Yes, the official warnings section notes that Olcin has the potential to cause photosensitivity. This means that skin exposed to sunlight or artificial UV light may react with increased sensitivity, leading to potential sunburn or rash.


Q: What happens when people stop taking Olcin?

A: Regulatory guidance emphasizes completing the full prescribed course to prevent bacterial resistance. Official warnings also note that serious side effects, such as tendon issues, have been reported to occur and progress even after the medicine has been discontinued.


Q: Is Olcin a narcotic or controlled substance?

A: No, official regulatory classifications state that Olcin is an antibacterial drug. It is not listed as a narcotic or scheduled as a controlled substance by regulatory agencies like the DEA.


Q: Does Olcin have an expiration date I should watch?

A: Yes, as an approved drug product, Olcin is subject to regulatory requirements that mandate a clearly marked expiration date. This date is printed on the packaging and should be observed to ensure the medicine retains its efficacy and safety.


Q: What does the research say about Olcin's effectiveness compared to placebo?

A: Official documentation from regulatory sources provides research evidence to support the drug's use. This includes summaries of clinical trials, which often detail results comparing Olcin's effectiveness to a placebo or other active treatments.


Q: What is the most serious side effect listed for Olcin?

A: The most serious risks are outlined in the official warnings and the Boxed Warning. These include the potential for tendon rupture, nerve damage, central nervous system effects, and QT interval prolongation.


Q: Do older adults react differently to Olcin?

A: Yes, official documents for specific populations note that older adults, defined as patients over 60 years of age, may be at a higher risk for certain serious side effects. This increased risk is specifically noted for conditions such as tendon rupture.


Q: What if I vomit shortly after taking Olcin?

A: Official documents generally advise against taking a second dose immediately if vomiting occurs shortly after the first dose. Instead, regulatory documents advise patients to contact a healthcare provider for advice regarding re-dosing.


Q: Is it safe to use Olcin if I have liver problems?

A: Official warnings mention a risk of liver damage, known as hepatotoxicity, associated with the use of this medicine. Official product information notes that patients with pre-existing liver problems may require close monitoring during treatment.

How should Olcin be stored and disposed of?

How to Store and Dispose of Olcin?


Official Storage Requirements

Based on regulatory labeling, Olcin must be stored at Controlled Room Temperature (typically 20 C to 25 C). It is essential to protect the medicine from light and moisture by keeping it in its original, tightly closed container. The label states Do not freeze and warns against exposure to excessive heat. Olcin must be stored out of the sight and reach of children at all times.


Stability and Disposal

If the product requires reconstitution or is opened, note the in-use stability period, which is typically 28 days, and discard any unused portion after this time. Do not use Olcin past the expiration date printed on the package. Proper disposal requires utilizing an authorized drug take-back program. If a take-back program is unavailable, follow specific label instructions, which usually involve mixing the product with an undesirable substance before discarding it in the household trash. Do not dispose of Olcin in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olcin found in:

A-Z Index: